Magnetic resonance imageable macromolecular probes for the diagnosis of solid malignancies and inflammatory disease states

Hemant Sarin
Freelance Investigator in Translational Science and Medicine, USA

The potential to characterize differences in hyperpermeability associated with diaphragm fenestrated tumor capillary neoangiogenesis, and that associated with capillariovenular inter-endothelial junction widening in non-tumor inflammation, with magnetic resonance imaging (MRI) exists. To-date, dynamic contrast-enhanced magnetic resonance imaging, has relied on the utilization of small molecule contrast agents (ie Gd-DTPA or Gd-DOTA) for the kinetic bicompartimental modeling of small molecule contrast agent wash-in (Ktrans) and wash-out (Kep) vascular parameters, of tumor hyper-permeability, in order to increase the diagnostic sensitivity of MRI to differentiate tumor type and grade. However, sequential imaging with macromolecular contrast agents, with time for washout of small molecule contrast agent, affords the added benefit of non-model-based quantitative characterization of hyper-permeability patterns, with the potential to delineate differences between contrast enhancement patterns of pathologic tumor hyper-permeability and inflammatory hyper-permeability. With the multitude of clinical safety data on FDA-approved Gd-DTPA based macromolecular contrast agents (Gadomer-17; ~4 nm) and pre-clinical animal data on larger macromolecular dendritic nanoparticle-based contrast agents with diameters in the 6 to 14 nanometer-size range, and improved specificity to discriminate physiologic hyper-permeability (i.e. muscle) from pathologic hyperpermeability, will be more sensitive for discrimination between pathologic tumor hyper-permeability and inflammatory hyper-permeability and useful towards the accurate non-invasive diagnosis of disease states of pathologic hyperpermeability. In this didactic discussion, the current state of the knowledge on MR imageable dendritic nanoparticle-based macromolecular probes will be presented, and the future perspective offered.

Biography

Hemant Sarin earned his Bachelor of Science in Biology with Highest Honors (1994) followed by a Medical Doctorate (1999) and went on to gain experience in Neurosurgery (2000-2003) prior to completing the NIH Imaging Sciences Program while developing his Translational Imaging-based Malignant Glioma Research Program concomitantly (2004-2009). He went on to gain additional intensive experience in Neurology for 6 months (2010), International Science Policy for 6 months (2011) and American Board Eligibility in Occupational and Environmental Medicine (2012-2014) while earning his Master of Science degree concomitantly on the conserved basis of toxin and toxicant interactions in the physiologic state.

hemantsarin74@gmail.com